Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 15/20 | 0.51 |
| ▸ | CA2 | P00918 | 15/20 | 0.51 |
| ▸ | CA12 | O43570 | 7/20 | 0.51 |
| ▸ | CA9 | Q16790 | 7/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 8/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672939 | 1.00 | CA1 (0.51) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL10165487 | 0.88 | MMP2 (0.40) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4879306 | 0.86 | MEN1 (0.42) | ALDH1A1GAACYP1A2HSD17B10L3MBTL1 | |
| SCHEMBL10165505 | 0.86 | POLB (0.46) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4944238 | 0.85 | KMT2A (0.43) | ALDH1A1GAAGFERHSD17B10L3MBTL1 | |
| SCHEMBL11910040 | 0.85 | MAPT (0.40) | ALDH1A1GAAKMT2A | |
| SCHEMBL4879389 | 0.85 | L3MBTL1 (0.41) | CA1CA2CA12CA9ALDH1A1 | |
| SCHEMBL4944245 | 0.85 | KMT2A (0.43) | ALDH1A1GAAGFERHSD17B10L3MBTL1 | |
| SCHEMBL11910039 | 0.85 | MAPT (0.40) | ALDH1A1GAAKMT2A | |
| SCHEMBL10165431 | 0.85 | KMT2A (0.43) | ALDH1A1GAAGFERHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101687782-A | Ion channel modulators and methods of use thereof | VERTEX PHARMA | 2010-03-31 | — | — | CN | disclosed |
| EP-2158183-A2 | ION CHANNEL MODULATORS AND METHODS OF USE | Vertex Pharmaceuticals Incorporated (US) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008147797-A2 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | CA1 916/4885CA2 192/4885CA12 2889/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | CA1 916/4885CA2 192/4885CA12 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.